- For the majority of patients in the DOVATO arm, the introduction of 2 new antiretrovials may have contributed to the differences in
drug-related AEs grade 2 to grade 5.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie . Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Dovato is a registered trade mark of the ViiV Healthcare group of companies or its licensor.
Date of preparation: October 2021 PM-IE-DLL-WCNT-200020